Abstract:Triple-Negative Breast Cancer (TNBC) patients that do not respond to neoadjuvant chemotherapy account for 60-70% of all cases and are orphans of therapeutic alternatives after chemotherapy failure. Despite the great progress that has been made in the application of immune-based strategies, clinical opportunities for TNBC patients are still lacking. We aimed to investigate the molecular mechanisms leading to the activation of the TNBC immunological microenvironment, thus providing novel clues for the design and development of immune-based therapeutic approaches and adoptive immune cell therapies for TNBC patients. We analyzed consecutive TNBC cases treated at AUSL-IRCCS Hospital of Reggio Emilia from 2011 to 2017. 24 Tru-Cut biopsies were selected, comparing 12 patients with pathological complete response (pCR) after neoadjuvant treatment and 12 patients with cancer progression. Then, we performed a morphology-guided transcriptome profiling of the immune infiltrate using our GeoMx-Digital spatial profiler (DSP) to investigate which immune populations were associated with a more favorable outcome. The immune infiltrate of patients showing pCR was significantly enriched for activated Natural Killer (NK) cells, compared to patients with disease progression. Intriguingly, both T-helper CD4- and CD8-T lymphocytes did not reach statistical significance, suggesting a secondary involvement in predicting neoadjuvant efficacy in TNBC patients. We confirmed that NK cells can significantly impair TNBC cell proliferation and viability in vitro and improved the efficacy of chemotherapeutic drugs (paclitaxel, docetaxel). To increase our knowledge of the molecular mechanisms governing NK effector functions toward TNBC, we decided to investigate the specific transcriptional landscape that triggers NK cell activation. We profiled the transcriptome of activated NK cells by RNA-sequencing, identifying several de-regulated pathways involved in NK innate anti-tumor response, including the down-regulation of Immune checkpoint (IC) molecules (CTLA4, CEACAM3, PD1, KIR2DL4, KIR3DX1, KIR3DL3, TIGIT, TIM3, LAG3, etc) and the up-regulation of vesicle-trafficking and autophagy-related proteins (STX5, STX7, BNIP3L, SNAP29, GABARAPL1, RAB4B, etc). To predict upstream transcription regulators, promoters of de-regulated genes were in silico scanned for common binding motifs with the FIMO algorithm, thus identifying a list of candidate Transcription Factors (TFs). Among top-scoring TFs, we identified PAX5 which has been already involved in NK differentiation and cytotoxicity. Other top-scoring TFs are currently under investigation as potential NK Master Regulators of their effector functions, including SMAD3, VEZF1, and MAZ. Overall, our results point out the relevance of NK cells in predicting neoadjuvant treatment response in TNBC patients. Moreover, the modulation of the NK transcriptional program may be a novel tool to potentiate their anti-tumor potential, thus proving novel clues to optimize their application in adoptive cell therapies and in the treatment of TNBC patients. Citation Format: Francesca Reggiani, Benedetta Donati, Moira Ragazzi, Veronica Manicardi, Federica Torricelli, Elisabetta Sauta, Elisa Gasparini, Simonetta Piana, Valentina Sancisi, Alessia Ciarrocchi. Deciphering natural killer transcriptional activation in triple-negative breast cancer: A novel opportunity for adoptive cell therapies? [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl) nr A22.

Blocking PCNA interaction with NKp44 enhances primary natural killer cell-mediated lysis of triple-negative breast cancer cells

The Combination of Anti-Kir Monoclonal Antibodies with Anti-Pd-1/pd-l1 Monoclonal Antibodies Could Be a Critical Breakthrough in Overcoming Tumor Immune Escape in NSCLC

Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer

Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis

Abstract A22: Deciphering natural killer transcriptional activation in triple-negative breast cancer: A novel opportunity for adoptive cell therapies?

Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

Abstract 367: Nano-immunotherapy in TNBC: Aptamer-based nanoparticles for PD-L1 siRNA delivery to cancer cells

Abstract P2-04-27: CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer

Regulation of DNA-PK activity promotes the progression of TNBC via enhancing the immunosuppressive function of myeloid-derived suppressor cells

Abstract 128: NKILA Lncrna Promotes Tumor Immune Evasion by Mediating Activation-Induced Cell Death in Tumor-Specific CTLs

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

Modulating Lncrna NKILA in Tumor-Reactive T Cells to Enhance Their Trafficking to Breast Cancer by Inhibition of FasL-induced T-cell Apoptosis.

Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells

Abstract 1399: The role of CCN5 in regulation of tumor-infiltrating lymphocytes (TILS) in triple-negative breast cancer (TNBC) cells

Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer

Blocking LBH expression causes replication stress and sensitizes triple-negative breast cancer cells to ATR inhibitor treatment

MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer

Abstract 307: Blocking LBH overexpression sensitizes triple negative breast cancer cells to ATR inhibition therapy

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody